• vcard
D 314.552.6850
F 618.655.9500
  • Education
    • M.S., University of Nebraska, 2000, Molecular Biology and Biochemistry; with distinction
    • J.D., University of Nebraska, 1994, with distinction
    • B.S., Iowa State University, 1990, Animal Science with an emphasis in Chemistry and Biochemistry; with honors
  • Bar Jurisdictions
    • Illinois, 2010
    • Missouri, 2000
    • Nebraska, 1995
    • Admitted to practice before the United States Patent and Trademark Office
Kathryn “Kate” Doty’s practice is devoted to patent law, particularly to the development, management and enforcement of worldwide patent portfolios that have included branded pharmaceutical products with multi-billion dollar annual sales. She has extensive experience counseling pharmaceutical companies, life science companies, and chemical companies, including Fortune 500 companies, mid-cap companies as well as emerging growth companies, and universities. Kate works to thoroughly understand her client’s business, and designs a comprehensive patent strategy to achieve their business objectives while helping to avoid infringement of competitors' patents.

Kate has significant experience preparing opinions related to infringement and validity in the pharmaceutical, life sciences and chemical fields. She counsels clients on freedom to operate issues and prepares patent landscape analysis of cutting edge areas of technology. Kate has extensive experience in preparing legal opinions to support Paragraph IV certifications for Abbreviated New Drug Applications (ANDA) under the Hatch-Waxman Act.

Kate also has considerable experience evaluating the strengths and weaknesses of patent portfolios in connection with acquisitions. She understands the interplay of how patent exclusivity and non-patent exclusivity, such as regulatory law, impact the value of an acquisition. As a result, Kate frequently serves as outside patent counsel to branded and generic pharmaceutical companies, life science companies, and chemical companies in acquisitions involving products ranging from multi-million dollar annual sales to multi-billion dollar annual sales.

Kate has worked on a range of technologies including animal feed supplements and additives, human nutritional supplements, nucleic acid chemistry, protein chemistry including recombinant protein production and purification, carbohydrate chemistry, combinatorial chemistry, immunology, vaccines, engineered tissues for use as vasculature or cartilage replacement, stem cells, contrast agents for use in MRI and optimal imaging, bioactive conductive polymers, microalgae for biofuels, high throughput screening methods, and on a wide variety of pharmaceutical products that include small organic molecules and peptides for treating pain, inflammation, high blood pressure, blood coagulation, cancer and several other indications or disease states.